Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Files An 8-K Regulation FD Disclosure
Adverum Biotechnologies, Inc. Exhibit
EX-99.1 2 d796347dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Adverum Biotechnologies Reports Positive 24-Week Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy to Treat Wet AMD — Zero anti-VEGF rescue injections required after one-time intravitreal dose of ADVM-022 — — Sustained improvements in retinal anatomy — — Was safe and well tolerated — — Data being presented during podium presentation at Retina Society 2019 Annual Meeting — — Adverum to host conference call and webcast on Thursday,…
To view the full exhibit click
About Adverum Biotechnologies, Inc. (NASDAQ:ADVM)
Adverum Biotechnologies, Inc., formerly Avalanche Biotechnologies, Inc., is a gene therapy company. The Company is engaged in discovering and developing medicines to patients suffering from chronic or debilitating disease. The Company operates and manages its business in the segment of developing and commercializing gene therapeutics. It focuses on diseases with unmet medical need, including ophthalmic diseases, such as wet age-related macular degeneration (AMD), as well as rare genetic diseases. The Company’s product candidates include AVA-101 and AVA-201 for treatment of Wet AMD; AVA-322 and AVA-323 for the treatment of Color Vision Deficiency, and AVA-311 for the treatment of Juvenile X-linked Retinoschisis. It has generated human proof-of-concept data for AVA-101 in a Phase I trial with over eight wet AMD subjects conducted at Lions Eye Institute (LEI) in Australia. It is developing AVA-322 and AVA-323 for the treatment of color vision deficiency (CVD).